Signalling pathways leading to IFN-α production in human plasmacytoid dendritic cell and the possible use of agonists or antagonists of TLR7 and TLR9 in clinical indications

Authors: Guiducci, C.; Coffman, R. L.; Barrat, F. J.

Source: Journal of Internal Medicine, Volume 265, Number 1, January 2009 , pp. 43-57(15)

Buy & download fulltext article:

You have access to the full text article on a website external to ingentaconnect.

Please click here to view this article on Wiley Online Library.

You may be required to register and activate access on Wiley Online Library before you can obtain the full text. If you have any queries please visit Wiley Online Library

Abstract:

. Guiducci C, Coffman RL, Barrat FJ (Dynavax Technologies Corporation, Berkeley, CA, USA). Signalling pathways leading to IFN-α production in human PDC and the possible use of agonists or antagonists of TLR7 and TLR9 in clinical indications (Review). J Intern Med 2008; 265: 43-57.

Plasmacytoid dendritic cells (PDC) are highly specialized immune cells capable of producing large amounts of type I and III IFN in response to viral infection. This response is mediated through TLR7 and TLR9 signalling pathways. In addition, PDC can differentiate into fully mature dendritic cells able to efficiently crosspresent viral antigens, thus playing an important role in adaptive immunity. This dual property of PDC is being used in clinical settings where synthetic TLR7 and TLR9 ligands are currently evaluated in clinical trials for the treatment of viral infections, allergies and cancers. Interestingly, there is evidence suggesting that chronic activation of PDC by endogenous RNA and DNA containing immune complexes maybe an important mechanism of driving autoimmunity and significant efforts to develop bi-functional antagonists of TLR7 and TLR9 are currently underway.

Keywords: autoimmunity; innate immunity; TLR7; TLR9

Document Type: Research article

DOI: http://dx.doi.org/10.1111/j.1365-2796.2008.02050.x

Publication date: 2009-01-01